KZIA 30min TF Scalptest Kazia Therapeutics Ltd. is a clinical stage oncology company It engages in the pharmaceutical research and development business. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.test Kazia Therapeutics Ltd. is a clinical stage oncology company It engages in the pharmaceutical research and development business. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.Longby TheCryptoChartWhisperer2
$KZIA looks good for a parabolic runLooks extremely bullish - definitely watching this stock. If price drops to $9, definitely a buy. Australia based firm has some key cancer drugs in the pipeline. (1) Price above Kumo (2) Future Kumo bullish (3) Senkou span A & B with positive slope (4) Both Tenkan Sen & Kijun Sen have +ve slopes (5)Looks extremely bullish - definitely watching this stock. If price drops to $9, definitely a buy. Australia based firm has some key cancer drugs in the pipeline. (1) Price above Kumo (2) Future Kumo bullish (3) Senkou span A & B with positive slope (4) Both Tenkan Sen & Kijun Sen have +ve slopes (5)Longby arindamsen11
It already started spinning upTHIS stock is in a resistance right now, the price reaction in this resistance will depend on the continuity of this emerging trendTHIS stock is in a resistance right now, the price reaction in this resistance will depend on the continuity of this emerging trendLongby FranzSavantTrader1
MONDAY MANIAIt's another week full of expectations. How would this go about? Would really be watching this closely.It's another week full of expectations. How would this go about? Would really be watching this closely.by Piplott122
KZIA: Higher price rejection after gap upHigher price rejection after spike and gap up. May retrace and fill gap. If confirmed PT1 = 5,82 PT2 = 4,52 (for gap fill)Higher price rejection after spike and gap up. May retrace and fill gap. If confirmed PT1 = 5,82 PT2 = 4,52 (for gap fill)Shortby LeLaf220
FDA Grants RPDD to Paxalisib for DIPGUS FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG Key Points With RPDD granted, Kazia may now be eligible to receive a 'rare pediatric disease priority review voucher' (PRV) if paxalisib is approved for DIPG A PRV grants the holder an expedited six-month review of a neUS FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG Key Points With RPDD granted, Kazia may now be eligible to receive a 'rare pediatric disease priority review voucher' (PRV) if paxalisib is approved for DIPG A PRV grants the holder an expedited six-month review of a neby AlenCiken0
Pre-market gainers scann (August 07)Pre-market gainers scannPre-market gainers scann01:18by Stockeris1
KZIA Leading Diagonal Wave 5 beginsHello, What is KZIA? Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastomaHello, What is KZIA? Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastomaLongby keifer3315
Bullish future for KZIA$KZIA Positive Overall Survival in Glioblastoma Study Kazia expects to present further data in 2H CY2020 Sales in excess of US$ 1 billion per annum treatment for glioblastoma$KZIA Positive Overall Survival in Glioblastoma Study Kazia expects to present further data in 2H CY2020 Sales in excess of US$ 1 billion per annum treatment for glioblastomaLongby Time_Oracle227